|
Semaglutide Patent Expiry in India Enables 70–90% Cheaper Generic Versions
Patent expiry of semaglutide has enabled launch of multiple generic versions in India, leading to price reduction of 70 to 90 %. The development impacts treatment access for obesity and type 2 diabetes.
Semaglutide and Generic Drugs:
| Dimension | Key Details |
|---|---|
| Obesity | Provides chronic disease defined by excess body fat with BMI of 30 or higher |
| Causes | Comprises genetic socioeconomic and lifestyle factors including excess calorie intake |
| Health Risks | Includes cardiovascular disease type 2 diabetes hypertension cholesterol liver disease sleep apnea and cancers |
| India Diabetes Burden | India has around 77 to 101 million adults with type 2 diabetes |
| Semaglutide | Provides prescription drug used for type 2 diabetes and obesity management |
| Drug Class | Belongs to GLP 1 receptor agonist class |
| Mechanism | Provides mimic of GLP 1 hormone reducing hunger and increasing satiety leading to lower calorie intake |
| Comparator Drug | Tirzepatide acts as dual GIP and GLP 1 agonist |
| Generic Drugs | Provides bioequivalent medicines with same active ingredient dosage safety and efficacy as branded drugs |
| Regulator | Central Drugs Standard Control Organisation regulates generic medicines in India |
| Patent Duration | Provides 20 year protection from date of filing under WTO TRIPS framework |
| India Patent Law | Section 3d of Patents Act 1970 prevents evergreening of patents |
| Price Impact | Generic entry has reduced prices of semaglutide by 70 to 90 percent |
| Jan Aushadhi Scheme | Provides affordable generic medicines through government outlets under PMBJP |
| Generic Variants | Includes Semanat Semafull Semaglyn Mashema Alterme and Noveltreat along with injector devices such as Semanext Livarise and Sembolic |